STOCK TITAN

GeoVax Labs appoints Anna Skowron as CFO

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

GeoVax Labs, Inc. (GOVX) reported several leadership changes: Mark W. Reynolds resigned as chief financial officer and corporate secretary effective November 13, 2026; the board appointed Anna Skowron as CFO effective November 16, 2026; and Kelly T. McKee, M.D., was terminated as chief medical officer effective November 17, 2026. Skowron also serves as principal financial officer and principal accounting officer on a fractional basis.

GeoVax agreed to pay BPC Consulting Ltd. $10,000 per month, plus applicable taxes, for Skowron’s services. The company also pays interim CEO and Board Chairman Tyler O’Brien $15,000 per month under an agreement effective November 5, 2026; his interim service lasts until a permanent principal executive officer is appointed or designated. Both consulting agreements allow termination on 90 days’ prior written notice.

Filing Explained

The added terms allow conditional incentives and equity-plan participation, while setting fee payments if GeoVax terminates either agreement without notice.

GeoVax terminated Chief Medical Officer Kelly T. McKee effective November 17, 2026; its CFO and interim-CEO consulting agreements also provide potential incentive compensation and specify fees if the company ends either agreement without 90 days’ notice.

BPC, which provides Anna Skowron’s CFO services, and Tyler O’Brien are eligible for the company’s incentive, bonus and equity-based plans on substantially the same terms offered to management and executives.

BPC may also receive a performance-based bonus if the annual report and year-end audit are completed successfully, with the amount and terms to be agreed in writing before the audit begins.

If GeoVax ends the CFO agreement without notice, it owes BPC notice-period fees based on its average monthly invoices in the preceding three months; for O’Brien, the payment is based on the monthly compensation rate then in effect.

O’Brien’s monthly rate may be reviewed and adjusted, but cannot be reduced without his prior written consent.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Monthly consulting fee $10,000 per month, plus applicable taxes GeoVax pays BPC Consulting Ltd. for Anna Skowron’s services
Monthly compensation $15,000 per month GeoVax pays interim CEO Tyler O’Brien under his consulting agreement
Termination notice 90 days’ prior written notice Either party may terminate either consulting agreement with this notice
principal financial officer regulatory
"will also serve as the Company’s principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
compensation recovery policy regulatory
"subject to the Company’s compensation recovery policy"
Rule 10D-1 regulatory
"adopted pursuant to Rule 10D-1 under the Exchange Act"
General Corporation Law of the State of Delaware regulatory
"permitted under the General Corporation Law of the State of Delaware"
A state-level statutory framework that acts like a widely used rulebook for how corporations are formed, governed, and dissolved in Delaware. It sets binding rules on directors’ powers, shareholder rights, mergers, and fiduciary duties, and matters to investors because it creates predictable legal outcomes and clear governance standards—like playing a game with well-known rules—affecting control, takeover risk, and the protection of shareholder interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is GeoVax’s new CFO?

GeoVax appointed Anna Skowron as chief financial officer effective November 16, 2026. She also serves as the company’s principal financial officer and principal accounting officer as a non-employee officer designated by BPC Consulting Ltd.

What are the monthly fees for GeoVax’s interim CFO and CEO consultants?

GeoVax pays BPC Consulting Ltd. $10,000 per month, plus applicable taxes, for Anna Skowron’s services. The company pays interim CEO Tyler O’Brien $15,000 per month under his consulting agreement.

What notice is required to end GeoVax’s CFO consulting agreement?

Either party may terminate the agreement on 90 days’ prior written notice. If GeoVax terminates without giving that notice, it will pay BPC the fees that would have been payable during the notice period, based on BPC’s average monthly fees invoiced during the preceding three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000832489 0000832489 2026-11-13 2026-11-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): November 13, 2026
 
GEOVAX LABS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39563
87-0455038
(State or other jurisdiction of
incorporation or organization)
(Commission File No.)
(IRS Employer Identification No.)
 
1955 Lake Park Drive, Suite 300
Smyrna, Georgia 30080
(Address of principal executive offices) (Zip code)
 
(678) 384-7220
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
GOVX
The Nasdaq Capital Market
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Resignation of Chief Financial Officer
 
On November 13, 2026, Mark W. Reynolds resigned as Chief Financial Officer and Corporate Secretary of GeoVax Labs, Inc. (the “Company”), and from all other officer positions with the Company and its subsidiaries, effective as of 5:00 p.m. Eastern Time on November 13, 2026. Mr. Reynolds also served as the Company’s principal financial officer and principal accounting officer.
 
Appointment of Interim Chief Financial Officer
 
On November 14, 2026, the Board of Directors (the “Board”) of the Company appointed Anna Skowron as Chief Financial Officer of the Company, effective as of November 16, 2026. In this role, Ms. Skowron will also serve as the Company’s principal financial officer and principal accounting officer.
 
Ms. Skowron, 39, has served as a Director of BPC Consulting Ltd., an Ontario, Canada corporation that provides chief financial officer, accounting, financial reporting and other consulting services to public and private companies, since September 2025. Since March 7, 2025, she has served as Interim Chief Financial Officer of GridAI Technologies Corp.; since February 9, 2026, she has served as Fractional Chief Financial Officer of Powell Max Limited; and since August 2026, she has served as Fractional Chief Financial Officer of BioRestorative Therapies, Inc. From 2020 through June 2026, Ms. Skowron served as Principal of Skowron Accounting Professional Corporation, where she provided chief financial officer, accounting, financial reporting, mergers and acquisitions advisory and capital markets consulting services to public and private companies across a range of industries. During this period, she advised on financings and supported strategic transactions. Ms. Skowron holds a Bachelor of Commerce degree, with a Specialist in Accounting and a Major in Economics, from the University of Toronto.
 
In connection with Ms. Skowron’s appointment, the Company entered into a CFO Consulting Agreement, dated November 16, 2026 (the “CFO Consulting Agreement”), with BPC Consulting Ltd. (“BPC”), which has designated Ms. Skowron to perform the services thereunder as a non-employee officer of the Company. Ms. Skowron serves on a fractional basis. Under the CFO Consulting Agreement, Ms. Skowron oversees the Company’s accounting and financial reporting, including the preparation of the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”), and reports to the Company’s Chief Executive Officer and the Chairman of the Audit Committee. The Company will pay BPC $10,000 per month, plus applicable taxes, payable on the first day of each month. BPC is eligible to receive a performance-based bonus upon the successful completion of the Company’s annual report on Form 10-K and related year-end audit, in an amount and on terms to be mutually agreed in writing prior to commencement of the year-end audit, and is eligible to participate in the Company’s compensation, bonus incentive and equity-based compensation plans on substantially the same terms as are offered to the Company’s management and executives. The Company will reimburse BPC for reasonable business expenses and will indemnify Ms. Skowron in her capacity as Chief Financial Officer to the fullest extent permitted under the General Corporation Law of the State of Delaware (the “DGCL”). The engagement commenced on November 16, 2026, and continues until terminated. Either party may terminate the CFO Consulting Agreement on 90 days’ prior written notice. If the Company terminates the agreement without giving that notice, it will pay BPC the fees that would have been payable during the notice period, based on the average monthly fees invoiced by BPC during the three months before termination.
 
 

 
The foregoing description of the CFO Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the CFO Consulting Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Other than the CFO Consulting Agreement, there are no arrangements or understandings between Ms. Skowron and any other person pursuant to which she was appointed as an officer of the Company. There are no family relationships between Ms. Skowron and any director or executive officer of the Company, and there are no transactions in which Ms. Skowron has an interest requiring disclosure under Item 404(a) of Regulation S-K (other than the CFO Consulting Agreement).
 
Consulting Agreement with Interim Chief Executive Officer
 
As previously reported in the Company’s Current Report on Form 8-K filed with the SEC on November 9, 2026, the Board appointed Tyler O’Brien as Interim Chief Executive Officer and Chairman of the Board. On November 16, 2026, the Company entered into a Consulting Agreement with Mr. O’Brien, effective as of November 5, 2026 (the “O’Brien Consulting Agreement”), pursuant to which Mr. O’Brien serves as the Company’s Chief Executive Officer as a non-employee consultant. Mr. O’Brien serves on an interim basis, until a permanent principal executive officer is appointed or designated. The Company pays Mr. O’Brien $15,000 per month, payable on the first day of each month. The monthly rate is subject to periodic review and adjustment by the Board or its Compensation Committee, but may not be reduced without Mr. O’Brien’s prior written consent. Mr. O’Brien is eligible to participate in the Company’s incentive compensation, bonus and equity-based compensation plans on substantially the same terms as are offered to the Company’s management and executives, and any incentive-based compensation is subject to the Company’s compensation recovery policy adopted pursuant to Rule 10D-1 under the Exchange Act and Nasdaq Listing Rule 5608. The Company will reimburse Mr. O’Brien’s reasonable business expenses and will indemnify him in his capacity as an officer or director to the fullest extent permitted under the DGCL. Either party may terminate the O’Brien Consulting Agreement on 90 days’ prior written notice. If the Company terminates the agreement without giving that notice, it will pay Mr. O’Brien the fees that would have been payable during the notice period, based on the monthly compensation rate then in effect. Mr. O’Brien has waived all claims under any prior agreement with the Company, other than his rights to indemnification, advancement of expenses and exculpation as a director or officer, and any equity awards previously granted to him.
 
The foregoing description of the O’Brien Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the O’Brien Consulting Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Termination of Chief Medical Officer
 
On November 17, 2026, the Company terminated Kelly T. McKee, M.D., as the Company’s Chief Medical Officer, effective immediately.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit Number
Description
10.1*
CFO Consulting Agreement, dated as of November 16, 2026, between GeoVax Labs, Inc. and BPC Consulting Ltd.
10.2*
Consulting Agreement, dated as of November 16, 2026, between GeoVax Labs, Inc. and Tyler O’Brien.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
* Indicates management contract or compensatory plan or arrangement.
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date: November 19, 2026
 
GEOVAX LABS, INC.
By:
/s/ Tyler O’Brien
Tyler O’Brien
Interim Chief Executive Officer
 
 
 

Filing Exhibits & Attachments

6 documents

Keep reading